Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azilsartan vs olmesartan for mild to moderate primary hypertension
CTR20170459Phase 3Active
- Sponsor
- Hebei Renhe Yikang Pharmaceutical
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of azilsartan in essential hypertension, sponsored by Hebei Renhe Yikang Pharmaceutical. Started May 2017; status: active.
02
Drugs
azilsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20170459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170459.